These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36849918)

  • 1. Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study.
    Meng Q; Zhao J; Yu Y; Wang K; Ren J; Xu C; Wang Y; Wang G
    BMC Cancer; 2023 Feb; 23(1):191. PubMed ID: 36849918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
    Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
    Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world first-line treatment of patients with BRAF
    Martinelli E; Cremolini C; Mazard T; Vidal J; Virchow I; Tougeron D; Cuyle PJ; Chibaudel B; Kim S; Ghanem I; Asselain B; Castagné C; Zkik A; Khan S; Arnold D
    ESMO Open; 2022 Dec; 7(6):100603. PubMed ID: 36368253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer.
    Xu T; Li J; Wang Z; Zhang X; Zhou J; Lu Z; Shen L; Wang X
    Cancer Med; 2023 May; 12(9):10473-10484. PubMed ID: 36912150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Metastasectomy in the Multimodality Approach for
    Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
    Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.
    Price TJ; Hardingham JE; Lee CK; Weickhardt A; Townsend AR; Wrin JW; Chua A; Shivasami A; Cummins MM; Murone C; Tebbutt NC
    J Clin Oncol; 2011 Jul; 29(19):2675-82. PubMed ID: 21646616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).
    Goldstein J; Tran B; Ensor J; Gibbs P; Wong HL; Wong SF; Vilar E; Tie J; Broaddus R; Kopetz S; Desai J; Overman MJ
    Ann Oncol; 2014 May; 25(5):1032-8. PubMed ID: 24585723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States.
    Trunk A; Braithwaite M; Nevala-Plagemann C; Pappas L; Haaland B; Garrido-Laguna I
    J Natl Compr Canc Netw; 2022 Feb; 20(2):144-150. PubMed ID: 35130499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
    Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
    Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
    Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
    Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain.
    Martínez-Lago N; Fernández-Montes A; Covela M; Brozos EM; De la Cámara J; Méndez Méndez JC; Jorge-Fernández M; Cousillas Castiñeiras A; Reboredo C; Arias Ron D; Pellón Augusto ML; González Villarroel P; Graña B; Salgado Fernández M; Carral Maseda A; Vázquez Rivera F; Candamio Folgar S; Reboredo López M;
    BMC Cancer; 2021 Jan; 21(1):64. PubMed ID: 33446148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.
    Tural D; Batur S; Erdamar S; Akar E; Kepil N; Mandel NM; Serdengeçti S
    Tumour Biol; 2014 Feb; 35(2):1041-9. PubMed ID: 23996432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
    Stintzing S; Miller-Phillips L; Modest DP; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
    Eur J Cancer; 2017 Jul; 79():50-60. PubMed ID: 28463756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
    Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
    J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
    Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A
    Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.
    Sasaki Y; Hamaguchi T; Yamada Y; Takahashi N; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Nagai Y; Taniguchi H; Boku N; Ushijima T; Shimada Y
    Asian Pac J Cancer Prev; 2016; 17(2):539-43. PubMed ID: 26925640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
    Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
    World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study.
    Huang C; Gu X; Zeng X; Chen B; Yu W; Chen M
    BMC Cancer; 2021 Jan; 21(1):30. PubMed ID: 33413175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study.
    Chen Y; Zhu D; Yu Y; Chang W; Ye L; Feng Q; Xu P; Chen M; Ji M; Wei Y; Liu T; Xu J
    Clin Colorectal Cancer; 2024 May; ():. PubMed ID: 38845274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.